# Parkinson's Disease
<!-- toc -->
# Parkinson's Disease Treatment
## Carbidopa/Levodopa
*MOA:*:
* **Levodopa**: Dopamine precursor
* **Carbidopa**: Inhibits L-Dopa peripheral metabolism

*Uses:*: Parkinson's
* Primarily bradykinesia, rigidity and tremor
* Less effective on flat affect and shuffling gait

*SE:*
* **Dyskinesia (irreversible)**
* **Peak dosing effect**
* Adrenergic:
*  Tachycardia, arrhythmias, HTN
* **Behavioral**:
* Psychosis, hallucination, delusions, etc. (think excess dopamine)
* Orthostasis
* **N/V/D (Tolerance)**
* **“Wearing off” or “on-off effects”**

## Dopamine Agonists
### 1st Generation - Ergot Derivatives
**Bromocriptine**

*MOA:*: D2 agonist and D1 antagonist

*Use:*: **Adjunct** to Carb/Levo

**Titrate slowly**

*SE:*
* Orthostasis and arrhythmias
* Hallucinations
**Pergolide** (withdrawn from market - heart valve regurgitation)
### 2nd Generation - Non-Ergot Derivatives
**Pramipexole & Ropinirole**

*MOA:*: D2 Agonist

*Uses:*:
* Effective monotherapy patients
* Adjunct to reduce “on-off" effects

**Pramipexole -> Longer half-life**

**Contraindicated in pregnancy**

*SE:*
* Impulse control!
* Hallucination & sleepiness

### Amantadine
*MOA:*:
* Enhances DA release or blocks DA reuptake, muscarinic antagonist, NMDA receptor antagonist

*Use:*:
* Effective **Early** monotherapy patients
* **Adjunct to reduce motor side effects (bradykinesia & rigidity)**

*SE:*
* Hallucinations & insomnia
* NNV

### Apomorphine
*MOA:*: Dopamine Agonist

*Use:*: Reduce off time in advanced disease

**Emetogenic -> Must administer with antiemetic**

## Adjunct Agents in Parkinson's
### MAOIs
**Selegiline**
*MOA:*: MAOI-B inhibitor - prevents metabolism of DA

*Use:*:
* Early monotherapy
* Adjunct with Carb/Levo

**Reduces “Wearing off" time!**

**Contraindications** TCAs, SSRls, etc.

**Side effects:** Insomina, dyskinesia, nausea, headache, cardiac arrhythmias, **HTN**

### COMT inhibitors
**Tolcapone & Entacapone**

*MOA:*:
o Tolcapone -> CNS and peripheral COMT.
o Entacapone -> Peripheral COMT

*Use:*: **Adjunct for freezing and dyskinesia**

**Lower L-Dopa dose**

**Attenuates the wearing-off time**

### Deep Brain Stimulation

*Uses:*
* Lastline
* Improves tremor, rigidity, and bradykinesia

Able to reduce L-Dopa dose

Effect lasts 1-3 years


# Drugs for Other Movement Disorders
### Tourette's Syndrome
**Neuroleptics**: Haloperidol
* Very effective & SE
**Alpha-2 agonists**: Clonidine
* Transdermal Patch
* Rebound HTN when D/C'd

### Amyotrophic lateral sclerosis
**Baclofen**

*MOA:*: GABAP agonist

Used for **Spasticity**

*SE:*: withdrawal, abuse, overdose

**Riluzole**
*MOA:*: Decreases glutamate excitotoxicity
*Use:*: **Delay onset of ventilator-dependence**

### Benign essential tremor
**Anticonvulsant**: Primidone

MOA: Barbiturate like

**B-Blockers**

# Antipsychotic Agents - Typicals (FYI)
### General Characteristics
*MOA:* Block D2 receptors in Basal Ganglia, Frontal lobe, Limbic system

*Use:* 2nd line for Schizophrenia after atypicals D2 SE & Anticholinergic SE related to Potency

*SE:*
* **D2 blockade**
  * Motor side effects ([EPS](https://en.wikipedia.org/wiki/Extrapyramidal_symptoms), TD)
  * Prolactinemia (Pituitary)
  * NMS
* Anticholinergic: Dry mouth, constipation, Urinary retention , mydriasis
* Alpha blockade: Orthostasis & Impotence
* Histamine blockade: Sedation
* DAJSHT: Anti-Emetic (Gut)
* Prolong QT

### Typical Antipsychotics
**Chlorpromazine** (Low Potency)
* MOA: Blocks D2, **alpha 1**, **Histamine**, Muscarinic
* More Anticholinergic Symptoms

**Haloperidol** (High Potency)
* Mostly blocks D2
* More [EPS](https://en.wikipedia.org/wiki/Extrapyramidal_symptoms) symptoms

# Parkinson’s Disease Treatment Guidelines

<img src="https://accesspharmacy.mhmedical.com/data/books/dipi9/dipi9_c043f004.png" width="600" height="600" />

**New Diagnosis**
* MAO-I
* D2 agonist

**Early Onset**
* Amantadine

**Gold Standard** Carbidopa / Levodopa

**Dyskinesia**
* MOA-I
* COMT
* Deep brain stimulation
